paracortex and small germinal centres. This was from a patient with systemic vasculitis, a high erythrocyte sedimentation rate, but a low rheumatoid factor titre at the time of biopsy. We have not yet investigated the possibility that the numbers of CD5 positive B cells are increased in our rheumatoid nodes, but the findings in the case described support our view that rheumatoid lymphadenopathy is likely to be a systemic part of the disease process. A role for the CD5 positive cell population in autoimmune diseases has been suggested, based on studies of the Ly-1 positive B cells in murine models of autoimmune disease. Because of their ability to produce autoreactive antibodies which express cross-reactive idiotypes (CRI), encoded by unmutated Ig variable region germ line genes. We have since found (unpublished observations) that increased numbers of plasma cells containing such CRI are associated with rheumatoid factor activity in rheumatoid nodules. It will be interesting to see if surface CRI-bearing B lymphocytes in frozen sections of the nodes in our patients have shown that such CRI are highly expressed by CD5 positive B cells in fetal liver and cord blood at a clonal level (unpublished observations).

2 Mageed RA, Dearlove M, Goodall DM, Jefferis R. Immunogenic and antigenic epitopes of immunoglobulin VH: Monoclonal auto-
3 Crowley JJ, Goldstein RD, Schreinenhout RE, et al. Incidence of three cross-reactive idiotypes on human rheumatoid factor para-

Guidelines on oral anticoagulation: second edition

As a consultant haematologist who no longer takes anticoagulant clinics I read with interest the revised guidelines on oral anti-
5 coagulation.1 Probably the guidelines do represent an advance in that they attempt to standardise and simplify advice on desired INR ratios. It is a pity, however, that they still have to be based on a mixture of fact, fiction, and subjectivity. Even in 1990, so much anticoagulant practice is not based on the results of good, well structured clinical trials.

It is necessary to express a contrary view to the statement that patients taking oral anticoagulants when discharged from hospital should normally be referred to consultant haematologists for the control of outpatient treatment. Given the increasing clinical, laboratory, and managerial commitments of a consultant haematologist, anticoagulant con-
6 trol should assume a low priority. In my own experience control of short and long term anticoagulation can be adequately and safely done by general practitioners after a short, simple education programme.

Where specific problems of anticoagulation arise these are referred for consultant opinion and action. In such a system the patient benefits in that he or she remains clearly under the supervision of his or her general practitioner who is the person supervising all other treatment. The general practitioner is thus in the strongest position to advise the prescribing specialist as to when and if anticoagulant treatment may have become inappropriate or present an undue hazard in any one patient.

It is usually argued that haematologists should be involved in anticoagulant control because "the haematologist does it better". Doubtless, minute precision of INR control may be improved but it is also likely that any other person trained exclusively to take anticoagulant clinics end up as a thoroughly unsatisfactory professional experience. Whether such precision represents an improvement in the totality of individual patient care for the investment involved is quite another matter. Certainly, as a generalisation, for 90% of patients taking anticoagulants at least 90% of the time there is no major problem; when problems arise they are generally difficult whoever is involved in supervising anticoagulation, although it must be con-
7 ceded the haematologist in this situation is usually in the best position to give clear advice as to practical short term management. Despite good intentions most anti-
8 coagulant clinics end up as a thoroughly unsatisfactory professional experience. This is because they deliberately set out only to take responsibility for anticoagulation and not other clinical problems, such limited responsibility often results in the patient and other groups of doctors. If haematologists should be the people running anticoagulation it would be better for them to have sufficient resources to have total specialist control of all such patients and finally establish policies regarding duration of anticoagulation, indica-
9 tions, etc.

Surely it is time to take a step forward and either actively demythologise anticoagulant treatment and encourage general practition-
10 ers to take responsibility for anticoagulant control, with appropriate availability of support and help from consultant haematolog-
11 ists, or aim to have services to become fully equipped and resource to offer a comprehensive anticoagulant service and assume a much greater degree of patient responsibility.

AG SMITH
Department of Haematology, Royal South Hants Hospital, Graham Road, Southampton SO9 4PE

British Society for Haematology, British Committe
12 for Standardization in Haematology, Haemostasis and Thrombosis Task Force. Guidelines on oral anticoagulation: second edi-

Dr Davidson comments: I have read Alastair Smith's letter with interest and must say it is because of the concerns he expressed that the British Society for Haematology, through the British Committe for Standardization in Haematology and its Haemostasis and Thrombosis Task Force, felt it necessary to issue guidelines on oral anticoagulation in an attempt to improve standards of clinical practice.

Yes, clinical practice is uncontrolled. The recom-
14 mendations are based on available scientific data, plus a consensus of United Kingdom practices.

Beware of anticoagulant control becoming a "low priority" and a "thoroughly unsatis-
15 factory professional experience" for a consul-
16 tant haematologist—not very reassuring to the 0-25 million plus patients receiving this treatment in the United Kingdom.

Rather, "aim for haematology services becoming fully equipped and resource to offer a comprehensive anticoagulant service and assume much greater degrees of patient responsibility".

I do not think we are really at odds with Alastair Smith. I am sure he wishes to provide these patients with a high standard of service. That is what the guidelines are all about. Maybe he needs to persuade his general manager to provide the necessary resources—the guidelines will help in this respect.

Hypercalcaemia in lymphoma

I was interested in the letter of Drs Ellis, Beck, and Mondal about a case of hypercalca-
17 mia in lymphoma. There seem to have been a few errors and omissions, however, and I wonder whether these can be clarified—namically, (1) the serum calcium in particular and perhaps also the serum phosphate and albumin concentrations were not given; (2) in paragraph 4 the red blood cell count was given as 4·1 × 10\(^{11}\); should this have been "white cell count"? If so, what was the differential? (3) In view of the above errors, was this a case report of a Hodgkin's or a non-Hodgkin's lymphoma as the title of the letter could be taken to imply Hodgkin's disease presenting with hypercalcaemia?

Dr LUCKIT
Department of Haematology, Mayday University Hospital, Mayday Road, Torquay, Devon TQ1 4YE


Dr Ellis comments: I hope the following notes will clarify the points raised by Dr Luckit.

Correspondence

J Clin Pathol: first published as 10.1136/jcp.44.1.86-b on 1 January 1991. Downloaded from http://jcp.bmj.com/ on April 9, 2022 by guest. Protected by copyright.